Cipla shares slip over 3% despite inking weight loss drug distribution pact with Eli Lilly

The fall in the stock comes amid profit booking after it hit its 52-week high of ₹1,673 per equity share on October 23, in anticipation of the deal. The development was announced right as the markets closed on Thursday.

The scrip closed 3.68% lower at ₹1,584.60 apiece on Friday.

Under the agreement, Cipla has the rights to distribute and promote Yurpeak, the second brand of tirzepatide in India, the two companies said in a joint statement shared on the bourses by Cipla.

Tirzepatide, a prescription-based, first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, was launched in India by Lilly in March 2025 under the brand name Mounjaro.

This strategic agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities, where Lilly already has an established presence, it added.

Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro, the statement said.

Commenting on the deal, Winselow Tucker, President and General Manager of Lilly India, said: “The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly's commitment to expanding access to innovative treatments for chronic conditions.”

With India facing a growing burden of type 2 diabetes and obesity, broader availability of tirzepatide will ensure that more patients can benefit from this innovative therapy, Tucker added.

Cipla Global Chief Operating Officer Achin Gupta said, "With the introduction of Yurpeak (tirzepatide), we are stepping into obesity care with the same commitment and scale that have defined our efforts in respiratory and chronic therapies".

The partnership with Lilly reflects Cipla's resolve to address one of the most pressing health concerns and offer patients innovative, accessible solutions that can transform health outcomes, he added.

Yurpeak (tirzepatide) will be available in the KwikPen presentation, a multi-dose single-patient use pre-filled pen, it said.

Cipla has a total market capitalisation of ₹1.29 lakh crore, as of October 24, 2025, according to data on the NSE.